Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Blood Advances|October 13, 2021
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort studyCarlo Visco, Luigi Marcheselli, Roberto Mina, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 11, 2025
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert PanelArsene M Mekinian, Sophie Georgin-Lavaille, Marcela A Ferrada, et al.
International Journal of Antimicrobial Agents|August 15, 2023
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Philipp Koehler, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
The Lancet. Haematology|August 18, 2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
Cancers|November 26, 2022
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha SurveyChiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, et al.
Open Forum Infectious Diseases|March 19, 2026
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA RegistryJon Salmanton-García, Francesco Marchesi, Erica Mackenzie, et al.
Eclinicalmedicine|April 12, 2023
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Maria Gomes da Silva, et al.
Blood|September 20, 2022
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA surveyLivio Pagano, Jon Salmanton-García, Francesco Marchesi, et al.
Hematological Oncology|December 5, 2023
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registryPellegrino Musto, Jon Salmanton-García, Nicola Sgherza, et al.
Pageof 15